BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Wang K, Sun D. Cancer stem cells of hepatocellular carcinoma. Oncotarget 2018;9:23306-14. [PMID: 29796190 DOI: 10.18632/oncotarget.24623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
2 Molinari M, Kaltenmeier C, Samra P, Liu H, Wessel C, Lou Klem M, Dharmayan S, Emmanuel B, Al Harakeh H, Tohme S, Geller D, Tevar A, Hughes CB, Humar A, Bataller R, Behari J. Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients. Annals of Surgery Open 2021;2:e065. [DOI: 10.1097/as9.0000000000000065] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149. [PMID: 28854942 DOI: 10.1186/s12943-017-0712-x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 23.4] [Reference Citation Analysis]
4 Kong SY, Song JJ, Jin YQ, Deng MJ, Yan JX. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Acta Clin Belg 2022;:1-9. [PMID: 35587164 DOI: 10.1080/17843286.2022.2076791] [Reference Citation Analysis]
5 Hutcheson J, Witkiewicz AK, Knudsen ES. The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle 2015;14:3812-9. [PMID: 25714546 DOI: 10.1080/15384101.2015.1010922] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
6 Li X, Han Z, Cheng Z, Yu J, Yu X, Liang P. Prognostic value of preoperative absolute lymphocyte count in recurrent hepatocellular carcinoma following thermal ablation: a retrospective analysis. Onco Targets Ther 2014;7:1829-35. [PMID: 25336974 DOI: 10.2147/OTT.S69227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Lin CC, Hsu CW, Chen YC, Chang ML, Liang KH, Lai MW, Lin CL, Chien RN, Lin KH, Yeh CT. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics J 2020;20:57-68. [PMID: 31611591 DOI: 10.1038/s41397-019-0106-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Mao R, Liu J, Liu G, Jin S, Xue Q, Ma L, Fu Y, Zhao N, Xing J, Li L, Qiu Y, Lin B. Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis. Oncotarget 2017;8:26185-99. [PMID: 28412734 DOI: 10.18632/oncotarget.15428] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X, Calvisi DF. Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. Front Oncol 2019;9:1412. [PMID: 31921669 DOI: 10.3389/fonc.2019.01412] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
10 Ouyang G, Pan G, Xu H, Wu Y, Liu Z, Lu W, Yi B, Chen X. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2020;54:675-81. [PMID: 32569032 DOI: 10.1097/MCG.0000000000001384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Gougelet A, Sartor C, Bachelot L, Godard C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B, Perret C, Colnot S. Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut 2016;65:1024-34. [PMID: 25792709 DOI: 10.1136/gutjnl-2014-308969] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
12 Gnoni A, Licchetta A, Memeo R, Argentiero A, Solimando AG, Longo V, Delcuratolo S, Brunetti O. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies. Medicina (Kaunas) 2019;55:E754. [PMID: 31766556 DOI: 10.3390/medicina55120754] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
13 Liu X, Liu F, Gao S, Reske J, Li A, Wu CL, Yang C, Chen F, Luo R, Xiao H. A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation. Cancer Lett 2017;391:152-61. [PMID: 28137631 DOI: 10.1016/j.canlet.2017.01.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, Zhang ZY, Lv JJ, Zhang Z, Chen ZN, Bian H. Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy. Front Cell Dev Biol 2019;7:233. [PMID: 31681766 DOI: 10.3389/fcell.2019.00233] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
15 Yang J, Zhang X, Liu L, Yang X, Qian Q, Du B. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway. Life Sci 2021;264:118711. [PMID: 33186566 DOI: 10.1016/j.lfs.2020.118711] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
17 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
18 Xiao H, Wang B, Xiong HX, Guan JF, Wang J, Tan T, Lin K, Zou SB, Hu ZG, Wang K. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. J Cell Physiol 2021;236:2572-91. [PMID: 32853412 DOI: 10.1002/jcp.30015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Sun L, Wang Y, Cen J, Ma X, Cui L, Qiu Z, Zhang Z, Li H, Yang RZ, Wang C, Chen X, Wang L, Ye Y, Zhang H, Pan G, Kang JS, Ji Y, Zheng YW, Zheng S, Hui L. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nat Cell Biol. 2019;21:1015-1026. [PMID: 31332348 DOI: 10.1038/s41556-019-0359-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
20 Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017;23:1015-1022. [PMID: 28340509 DOI: 10.1002/lt.24764] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
21 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
22 Unić A, Derek L, Duvnjak M, Patrlj L, Rakić M, Kujundžić M, Renjić V, Štoković N, Dinjar P, Jukic A, Grgurević I. Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis. Ann Clin Biochem 2018;55:355-62. [DOI: 10.1177/0004563217726808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Wang Q, Zhai YY, Dai JH, Li KY, Deng Q, Han ZG. SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma. Int J Biol Sci 2014;10:807-16. [PMID: 25076857 DOI: 10.7150/ijbs.9143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
24 Sylvester KG, Colnot S. Hippo/YAP, β-catenin, and the cancer cell: a "ménage à trois" in hepatoblastoma. Gastroenterology 2014;147:562-5. [PMID: 25072176 DOI: 10.1053/j.gastro.2014.07.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
25 Feng H, Yu Z, Tian Y, Lee YY, Li MS, Go MY, Cheung YS, Lai PB, Chan AM, To KF, Chan HL, Sung JJ, Cheng AS. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. J Hepatol 2015;62:1100-11. [PMID: 25500144 DOI: 10.1016/j.jhep.2014.11.040] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
26 Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle. 2017;16:499-507. [PMID: 28118080 DOI: 10.1080/15384101.2017.1282586] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
27 Mani SKK, Andrisani O. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells. Genes (Basel). 2018;9:137. [PMID: 29498629 DOI: 10.3390/genes9030137] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
28 Huang KW, Jayant K, Lee PH, Yang PC, Hsiao CY, Habib N, Sodergren MH. Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. J Clin Med 2019;8:E385. [PMID: 30893948 DOI: 10.3390/jcm8030385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
29 Senni N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, Sartor C, Lagoutte I, Gougelet A, Terris B, Gilgenkrantz H, Perret C, Colnot S, Bossard P. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut 2019;68:322-34. [PMID: 29650531 DOI: 10.1136/gutjnl-2017-315448] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 18.3] [Reference Citation Analysis]
30 Tiniakos DG, Maurício J, Reeves HL. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View. Adv Exp Med Biol 2018;1032:55-69. [PMID: 30362090 DOI: 10.1007/978-3-319-98788-0_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Azparren-Angulo M, Royo F, Gonzalez E, Liebana M, Brotons B, Berganza J, Goñi-de-Cerio F, Manicardi N, Abad-Jordà L, Gracia-Sancho J, Falcon-Perez JM. Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities. Pharmacol Ther 2021;218:107683. [PMID: 32961265 DOI: 10.1016/j.pharmthera.2020.107683] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Shi Y, Zhai W, Wang B, Zhao D, Jin H, Wang Y, Zhang J, An H, Fu Z, Zhao K, Lu C. Genetic susceptibility of eight nonsynonymous polymorphisms in HLA-DRB1 gene to hepatocellular carcinoma in Han Chinese. Oncotarget 2016;7:80935-42. [PMID: 27821814 DOI: 10.18632/oncotarget.13111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
33 Savall M, Senni N, Lagoutte I, Sohier P, Dentin R, Romagnolo B, Perret C, Bossard P. Cooperation Between the NRF2 Pathway and Oncogenic β-catenin During HCC Tumorigenesis. Hepatol Commun 2021;5:1490-506. [PMID: 34510835 DOI: 10.1002/hep4.1746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Lai MW, Chu YD, Lin CL, Chien RN, Yeh TS, Pan TL, Ke PY, Lin KH, Yeh CT. Is there a sex difference in postoperative prognosis of hepatocellular carcinoma? BMC Cancer 2019;19:250. [PMID: 30894157 DOI: 10.1186/s12885-019-5453-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
35 Liu Z, Zhang Y, Shi C, Zhou X, Xu K, Jiao D, Sun Z, Han X. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. J Transl Med 2021;19:5. [PMID: 33407585 DOI: 10.1186/s12967-020-02697-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
36 Zahran AM, Abdel-Rahim MH, Refaat A, Sayed M, Othman MM, Khalak LMR, Hetta HF. Circulating hematopoietic stem cells, endothelial progenitor cells and cancer stem cells in hepatocellular carcinoma patients: contribution to diagnosis and prognosis. Acta Oncol 2020;59:33-9. [PMID: 31478425 DOI: 10.1080/0284186X.2019.1657940] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
37 Kim KM, Cho SS, Ki SH. Emerging roles of ferroptosis in liver pathophysiology. Arch Pharm Res 2020;43:985-96. [PMID: 33079307 DOI: 10.1007/s12272-020-01273-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wang D, Qi X, Liu F, Yang C, Jiang W, Wei X, Li X, Mi J, Tian G. A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk. Oncotarget 2017;8:50109-16. [PMID: 28187002 DOI: 10.18632/oncotarget.15202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
39 Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett 2015;356:971-7. [PMID: 25444922 DOI: 10.1016/j.canlet.2014.11.014] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 14.5] [Reference Citation Analysis]
40 Labib OH, Harb OA, Khalil OH, Baiomy TA, Gertallah LM, Ahmed RZ. The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver. J Gastrointest Canc 2020;51:88-101. [DOI: 10.1007/s12029-019-00211-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
41 Vega-Benedetti AF, Saucedo CN, Zavattari P, Vanni R, Royo F, Llavero F, Zugaza JL, Parada LA. PLAGL1 gene function during hepatoma cells proliferation. Oncotarget 2018;9:32775-94. [PMID: 30214684 DOI: 10.18632/oncotarget.25996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Ge Y, Chen S, Mu W, Ba Q, Li J, Chen P, Wang X, Wang H. Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma. Cancer Lett 2019;454:14-25. [PMID: 30910587 DOI: 10.1016/j.canlet.2019.03.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
43 Zekri ARN, El Deeb S, Bahnassy AA, Badr AM, Abdellateif MS, Esmat G, Salama H, Mohanad M, El-dien AE, Rabah S, Abd Elkader A. Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. World J Gastroenterol 2018; 24(11): 1228-1238 [PMID: 29568203 DOI: 10.3748/wjg.v24.i11.1228] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
44 Hua HW, Jiang HS, Jia L, Jia YP, Yao YL, Chen YW, Jiang F, Lu DQ, Zhou Q, Jiang MW, Ding G. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma. Cancer Biomark 2021. [PMID: 33843664 DOI: 10.3233/CBM-200101] [Reference Citation Analysis]
45 Shi YH, Wang B, Xu BP, Jiang DN, Zhao DM, Ji MR, Zhou L, Li X, Lu CZ. The association of six non-synonymous variants in three DNA repair genes with hepatocellular carcinoma risk: a meta-analysis. J Cell Mol Med 2016;20:2056-63. [PMID: 27306318 DOI: 10.1111/jcmm.12896] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
46 Li J, Wang J, Zhou W, Zhang S, Le Y, He R. Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells. Oncol Lett 2017;14:4751-7. [PMID: 29085476 DOI: 10.3892/ol.2017.6770] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
47 Zheng W, Yao M, Sai W, Qian Q, Pan L, Qiu L, Huang J, Wu W, Yao D. Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. Tumour Biol. 2016;37:999-1008. [PMID: 26264614 DOI: 10.1007/s13277-015-3875-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
48 Deuschle U, Birkel M, Hambruch E, Hornberger M, Kinzel O, Perović-Ottstadt S, Schulz A, Hahn U, Burnet M, Kremoser C. The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoprotein. Int J Cancer 2015;136:2693-704. [PMID: 25363753 DOI: 10.1002/ijc.29312] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
49 Choi JY, Yu JI, Park HC, David Kwon CH, Kim JM, Joh J, Choi G, Park JB, Kim SJ, Lee SH, Cho W, Lee KW, Na B, Oh DK, Lee N, Cho CW, Lee S, Lee S. The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Liver Transpl 2017;23:545-51. [DOI: 10.1002/lt.24729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
50 Bao J, Chen X, Hou Y, Kang G, Li Q, Xu Y. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway. Biomedicine & Pharmacotherapy 2018;107:824-33. [DOI: 10.1016/j.biopha.2018.08.079] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
51 Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]